Sensory neuropathies are a frequent and dose-limiting complication resulting from treatment with cisplatin. cisplatin; neuropathy Cisplatin is an efficient antineoplastic agent. However, its use is limited by its toxicity. The associated vomiting and nephrotoxicity are currently reduced by the use of antiemetics and vigorous hydration. The most problematic complication of cisplatin treatment is its neurotoxicity in the peripheral nervous system. Cisplatin causes a dosedependent and dose-limiting sensory neuropathy, which is often disabling and from which recovery is often slow and incomplete.
induced increase in sensory distal latencies. Similar effects were observed in cisplatin-treated mice that received intramuscular injections of a plasmid encoding NT-3 associated with in vivo electroporation. The two techniques were well tolerated and induced only slight muscle toxicity. Measurement of renal function, weight and survival showed that neither technique increased the toxicity of cisplatin. Our study shows that gene therapy, using either a viral or a nonviral vector, is a promising strategy for the prevention of cisplatin-induced neuropathy.
Gene Therapy (2002) 9, 1333-1337. doi:10.1038/sj.gt.3301801 circulation. 8 Intramuscular injection of a recombinant plasmid followed by electroporation provided significant protection against experimental cisplatin-induced neuropathy. On the other hand, intramuscular injection of an adenovirus encoding NT-3 is effective in other animal models of peripheral neuropathies, such as pure motor neuropathy in mice 9 and sensorimotor acrylamideand diabetes-induced neuropathies in rats. 10 Subcutaneous inoculation with a herpes simplex virus encoding NT-3 protects peripheral sensory axons from the neuropathies induced by intoxication with pyridoxine. 11 The latter results suggest that viral gene therapy may also be a promising means of treating sensory cisplatininduced neuropathy.
The aim of this work was to compare, in a mouse model of cisplatin-induced neuropathy, the efficiency and tolerability of NT-3 delivery using intramuscular injection of an adenoviral vector (AdNT-3) to that obtained with a recombinant plasmid (pNT-3) followed by electroporation. Gene therapy was performed 2 days before the initiation of cisplatin intoxication. NT-3 was detected in the plasma of mice treated with pNT-3 at the two highest doses (5 and 10 g/animal), but not in mice treated with 1 g/animal (Table 1) . Mice treated with AdNT-3 (10 9 p.f.u./animal) exhibited higher NT-3 plasma and muscle concentrations than mice treated with pNT-3. A kinetics study showed that after injection of pNT-3 or AdNT-3, NT-3 plasma levels were highest on day 7 and declined thereafter, but were still detectable on day 90, the last time point tested (Figure 1 ). Seven As described previously, 8, 10, 31 we used recombinant plasmids and ⌬E1, ⌬E3 adenoviruses encoding NT-3 (pNT-3 and AdNT-3, respectively) and ␤-galactosidase (p␤gal and Ad␤gal, respectively) under the control of the CMV promoter. OF1 mice (IFFA-Credo, L'Arbresle, France) were injected bilaterally in three muscle groups: gastrocnemius, tibialis cranialis and triceps brachii. In vivo electroporation was performed in animals treated with naked plasmid (pNT-3 or p␤gal) and the corresponding controls, as previously described. 8 In brief, immediately after DNA injection, electrodes were applied to each side of the muscle, straddling the injection site. Four square-wave pulses of 100 V (250 V/cm) and 20 ms duration were delivered to each muscle, at a frequency of 1 Hz. Forty-eight hours after gene therapy, mice were injected intraperitoneally with cisplatin (Sigma, St Louis, MO, USA; 10 mg/kg of body weight). These injections were repeated once a week for 5 weeks. NT-3 levels in plasma and muscle were measured by ELISA. 8 Values are expressed as means ± s.e.m. P values represent the significance versus untreated normal control mice (Mann-Whitney test). days after treatment, numerous NT-3-immunostained myofibers were detected in the muscles of mice treated with pNT-3 or AdNT-3 ( Figure 2 ). The adenoviral vector resulted in an expression area near the needle track, covering a volume of~15 mm 3 . In muscles treated with the plasmid and electroporation, the main expression area was near to the electrodes and covered a volume of 10 mm 3 . We examined whether treatment with gene therapy induced significant general or local toxicity. Systemic toxicity was evaluated by assessing renal function, weight and survival. As expected, mice treated with cisplatin alone (n = 40) developed severe renal failure. Six weeks after the treatment, the mean blood urea concentration was 3.2-fold higher in cisplatin-treated animals than in untreated controls (n = 40, P Ͻ 0.0001). The body weight of animals treated with cisplatin alone decreased to 85% of the pretreatment value, whereas the body weight of age-matched controls increased normally. The survival rate in cisplatin-treated animals was 32/40 (80%) at 6 weeks. Co-treatment with the plasmid and adenoviral vectors encoding NT-3 or ␤gal (20 animals/group) did not affect the weight loss, the increase in blood urea (ANOVA) or survival (log-rank test). Treatment with AdNT-3, which produced the highest concentrations of circulating NT-3, did not result in higher general toxicity. It can be assumed that the very low concentrations of NT-3 achieved by gene therapy, whatever the vector used, were below the toxicity threshold. However, we cannot exclude the possibility that the index used to evaluate general toxicity was not sensitive enough to detect a difference. Gene therapy did not induce major muscular toxicity, except for in a few centronucleated myofibers and slight endomysial inflammation for either vector (Figure 2) .
We assessed the efficacy of gene therapy on neuropathy by measuring the sensory distal latencies of the caudal nerve (Figure 3) , an index that we found to be more sensitive and more reproducible than the amplitudes of the sensory nerve. Preliminary experiments (10 9 pfu/animal) instead of pNT-3. Six days after the last injection, electrophysiological tests were performed on all surviving mice as described previously. 8 
Values are expressed as means ± s.e.m. in milliseconds. The asterisk (P Ͻ 0.0001) refers to the comparison between mice treated with gene therapy and mice treated with cisplatin alone (ANOVA). Differences between normal control and cisplatin-treated mice were highly significant (P Ͻ 0.0001).
revealed a significant difference between cisplatin-treated mice and controls after five injections of cisplatin. Electrophysiological assessments were performed 6 days after the fifth injection of cisplatin. A longitudinal study was not performed because the high mortality rate due to the renal toxicity of cisplatin hampered successive injections of the compound. Furthermore, preliminary experiments showed that repeated electrophysiological measurements resulted in a high death rate due to the accumulation of anesthetic products caused by renal insufficiency. As expected the sensory distal latencies were 21% higher in mice treated with cisplatin alone than in control mice (P Ͻ 0.0001). The cisplatin-related increase of sensory distal latencies was partially prevented by co-treatment with a dose of 5 or 10 g/mouse pNT-3 (P Ͻ 0.0001) (46% and 48% protection, respectively), but not by a dose of 1 g pNT3/mouse. Treatment with AdNT-3 ( 10 9 p.f.u./mouse) produced a similar therapeutic effect (43% protection, P Ͻ 0.0001), even though higher plasma NT-3 levels were obtained with this technique. The absence of an obvious relationship between the dose of NT-3 and effect could be related to the saturation of neurotrophic Gene Therapy factor receptors, which occurs at very low ligand concentrations. 12 We also investigated whether the delivery of NT-3 by gene transfer influenced sensory conduction in control animals, ie in the absence of cisplatin. Treatment of normal mice with pNT-3 (10 g/mouse) or AdNT-3 did not modify the conduction of sensory fibers, suggesting that gene therapy is effective against the pathological process of experimental neuropathy. Neurotrophin-3 can slow nerve degeneration by correcting a putative deficit in the neurotrophic factor. Although a lack of NT-3 has been shown in experimental diabetic neuropathy, [13] [14] [15] it has never been demonstrated in cisplatin-induced neuropathy. Alternatively, as NT-3 favors the survival of peripheral nerves following various types of injury, 16 its effect in cisplatin-induced neuropathy could result from a non-specific neuroprotection of the peripheral nerve.
The viral and non-viral techniques were comparable in terms of efficacy against the neuropathy and toxicity. The effect of treatment was demonstrated only on one electrophysiological parameter, ie the sensory distal latency of the caudal nerve. Sensory conduction is considered to be a reliable and sensitive method, and is extensively used as the primary evaluation criterion for new therapies for the treatment of cisplatin-related neuropathy. 17 It can detect early functional changes of the sensory nerve by exploring a large number of large sensory fibers, 18 which are specifically impaired in cisplatin-induced neuropathy.
1 This method appears to be the most sensitive, as cisplatin-treated mice did not exhibit any unambiguous invariant clinical signs or any unequivocal neuronal loss in dorsal root ganglia or sensory nerves. 19, 20 One of the limitations of this treatment is that plasma NT-3 concentrations decrease with time. Our findings are consistent with previous reports, showing a decrease in the systemic production of various proteins with time following muscle-targeted gene therapy using adenoviral vectors 10, 21 or naked DNA injection and muscle electroporation. 8, 22, 23 This suggests that a single injection is not sufficient for human therapeutic applications as cisplatin therapy generally involves repeated treatment over several months. In the case of adenoviral vectors, the immune reaction against viral proteins constitutes the main limitation preventing long-term expression, 21 and reducing the efficacy of subsequent repeat injections. However, this limitation may be circumvented by the development of new generations of viral vector that elicit lesser immune reactions, which should improve the duration of transgene expression. Indeed, long-term expression in plasma (>17 months) has been obtained after intramuscular injection of adeno-associated viral vectors. 24 Future studies are necessary to achieve durable NT-3 expression following a single injection of constructs based on these new viral vectors. One advantage of nonviral vectors is that they do not elicit an immune reaction and therefore allow reproducible transgene expression after repeat injections. This has been demonstrated for erythropoietin production by naked DNA injection and muscle electroporation. 23 Furthermore, despite the decline in transgene expression following this procedure, one report described erythropoietin production that lasted at least 14.5 months. 25 As low plasma levels of NT-3 can partially counteract cisplatin-induced neuropathy, frequent reinjections may not be necessary. However, the efficacy and safety of electroporation needs to be tested in larger animals before envisaging its application in humans.
These results show that intramuscular gene therapy can be used to deliver low circulating levels of NT-3 continuously, and that these low levels can produce a therapeutic effect with a minimal risk of toxicity. This strategy avoids one of the major limitations of treatment with recombinant neurotrophic factors, which at least partly explained the disappointing results obtained in clinical trials despite their efficiency in animal models of peripheral neuropathies. Indeed, because of the poor bioavailability of recombinant neurotrophic factors, high doses are necessary to be effective in animal models. 5, 6, 26 However, the side-effects of neurotrophic factors in humans prevent the administration of doses shown to be effective in animal studies. 27 For example, in a phase III trial of recombinant nerve growth factor (NGF) in a diabetesinduced neuropathy, 28 the dose used (0.3 g/kg/week subcutaneously) was 30 000-fold lower than that shown to produce a response in diabetic rats (9 mg/kg/week subcutaneously). 26 The treatment had no beneficial effects on diabetes-related polyneuropathy, but 67% of patients nevertheless suffered injection-site hyperalgesia. The systemic production of neurotrophic factors by gene therapy would also be more convenient and less costly than repeated injections of the purified protein. 29 In conclusion, muscular-based gene transfer strategies, involving viral or non-viral vectors, are promising methods for the prevention of cisplatin-induced sensory neuropathy. This approach may reduce the incidence of these disabling complications in patients with cancer and allow higher cumulative doses of cisplatin to be used to improve the anticancer effect. The feasibility of this novel therapeutic approach is supported by the fact that gene therapy for the treatment of peripheral neuropathies is already being tested in clinical trials. A recent clinical trial using non-viral muscular-based gene therapy to deliver the vascular endothelial growth factor (VEGF) to patients with chronic ischemic neuropathy showed that it is effective and safe. 30 Future improvements in gene therapy vectors will allow the selection of the most appropriate strategy, whether viral or non-viral, for clinical trials in the case of cisplatin-induced neuropathy.
